Skip to main content
Top
Published in: BMC Nephrology 1/2015

Open Access 01-12-2015 | Research article

Plasma levels of natriuretic peptides and development of chronic kidney disease

Authors: Noriyuki Ogawa, Hiroshi Komura, Kenji Kuwasako, Kazuo Kitamura, Johji Kato

Published in: BMC Nephrology | Issue 1/2015

Login to get access

Abstract

Background

Plasma levels of atrial and brain natriuretic peptides (ANP and BNP) are increased in patients with chronic kidney disease (CKD) complicated with deteriorated kidney function, but the relationship between the plasma level of ANP or BNP and the future development of CKD is unclear.

Methods

We measured the plasma ANP and BNP levels of 294 local residents without CKD in a Japanese community (56.5 ± 10.4 years, mean ± S.D.), who were followed up for the development of CKD over the next 7 years.

Results

Sixty-three residents developed CKD during the follow-up period, and the baseline level of plasma ANP of these residents was significantly higher than in those without CKD development. Kaplan-Meier analysis showed that the residents with higher ANP than the median value developed CKD more frequently than those with lower ANP. The association between plasma ANP level and CKD development was found to be independent of baseline estimated glomerular filtration rate by a Cox proportional hazards model, while this association became insignificant when adjusted by age; plasma ANP was significantly correlated with age. Compared with ANP, the relationship between plasma BNP and CKD development was unclear in these analyses.

Conclusions

Age-related elevation of plasma ANP levels preceded the development of CKD in the general population of Japan, raising a possibility for ANP being involved in the development of CKD.
Literature
1.
go back to reference Kangawa K, Matsuo H. Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (α-hANP). Biochem Biophys Res Commun. 1984;118:131–9.CrossRefPubMed Kangawa K, Matsuo H. Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (α-hANP). Biochem Biophys Res Commun. 1984;118:131–9.CrossRefPubMed
2.
go back to reference Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature. 1988;332(6159):78–81.CrossRefPubMed Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature. 1988;332(6159):78–81.CrossRefPubMed
4.
go back to reference Minamino N, Nishikimi T. Natriuretic peptides. In: Kastin AJ, editor. Handbook of biologically active peptides. San Diego: Academic; 2013. p. 1415–22.CrossRef Minamino N, Nishikimi T. Natriuretic peptides. In: Kastin AJ, editor. Handbook of biologically active peptides. San Diego: Academic; 2013. p. 1415–22.CrossRef
5.
go back to reference Kato J, Eto T. Natriuretic peptides. In: Martini L, editor. Encyclopedia of endocrine diseases. San Diego: Academic; 2004. p. 287–90.CrossRef Kato J, Eto T. Natriuretic peptides. In: Martini L, editor. Encyclopedia of endocrine diseases. San Diego: Academic; 2004. p. 287–90.CrossRef
7.
go back to reference Tripathi S, Pandey KN. Guanylyl cyclase/natriuretic peptide receptor-A signaling antagonizes the vascular endothelial growth factor-stimulated MAPKs and downstream effectors AP-1 and CREB in mouse mesangial cells. Mol Cell Biochem. 2012;368:47–59.CrossRefPubMedPubMedCentral Tripathi S, Pandey KN. Guanylyl cyclase/natriuretic peptide receptor-A signaling antagonizes the vascular endothelial growth factor-stimulated MAPKs and downstream effectors AP-1 and CREB in mouse mesangial cells. Mol Cell Biochem. 2012;368:47–59.CrossRefPubMedPubMedCentral
8.
go back to reference Ogawa Y, Mukoyama M, Yokoi H, Kasahara M, Mori K, Kato Y, et al. Natriuretic peptide receptor guanylyl cyclase-A protects podocytes from aldosterone-induced glomerular injury. J Am Soc Nephrol. 2012;23:1198–209.CrossRefPubMedPubMedCentral Ogawa Y, Mukoyama M, Yokoi H, Kasahara M, Mori K, Kato Y, et al. Natriuretic peptide receptor guanylyl cyclase-A protects podocytes from aldosterone-induced glomerular injury. J Am Soc Nephrol. 2012;23:1198–209.CrossRefPubMedPubMedCentral
9.
go back to reference Kasahara M, Mukoyama M, Sugawara A, Makino H, Suganami T, Ogawa Y, et al. Ameliorated glomerular injury in mice overexpressing brain natriuretic peptide with renal ablation. J Am Soc Nephrol. 2000;11:1691–701.PubMed Kasahara M, Mukoyama M, Sugawara A, Makino H, Suganami T, Ogawa Y, et al. Ameliorated glomerular injury in mice overexpressing brain natriuretic peptide with renal ablation. J Am Soc Nephrol. 2000;11:1691–701.PubMed
10.
go back to reference Nishikimi T, Inaba-Iemura C, Ishimura K, Tadokoro K, Koshikawa S, Ishikawa K, et al. Natriuretic peptide/natriuretic peptide receptor-A (NPR-A) system has inhibitory effects in renal fibrosis in mice. Regul Pept. 2009;154:44–53.CrossRefPubMed Nishikimi T, Inaba-Iemura C, Ishimura K, Tadokoro K, Koshikawa S, Ishikawa K, et al. Natriuretic peptide/natriuretic peptide receptor-A (NPR-A) system has inhibitory effects in renal fibrosis in mice. Regul Pept. 2009;154:44–53.CrossRefPubMed
11.
go back to reference Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med. 2010;170:507–14.CrossRefPubMed Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med. 2010;170:507–14.CrossRefPubMed
12.
go back to reference Yandle TG, Espiner EA, Nicholls MG, Duff H. Radioimmunoassay and characterization of atrial natriuretic peptide in human plasma. J Clin Endocrinol Metab. 1986;63:72–9.CrossRefPubMed Yandle TG, Espiner EA, Nicholls MG, Duff H. Radioimmunoassay and characterization of atrial natriuretic peptide in human plasma. J Clin Endocrinol Metab. 1986;63:72–9.CrossRefPubMed
13.
go back to reference Ishizaka Y, Yamamoto Y, Fukunaga T, Yokota N, Kida O, Kitamura K, et al. Plasma concentration of human brain natriuretic peptide in patients on hemodialysis. Am J Kidney Dis. 1994;24:461–72.CrossRefPubMed Ishizaka Y, Yamamoto Y, Fukunaga T, Yokota N, Kida O, Kitamura K, et al. Plasma concentration of human brain natriuretic peptide in patients on hemodialysis. Am J Kidney Dis. 1994;24:461–72.CrossRefPubMed
14.
go back to reference Spanaus KS, Kronenberg F, Ritz E, Schlapbach R, Fliser D, Hersberger M, et al. B-type natriuretic peptide concentrations predict the progression of nondiabetic chronic kidney disease: the mild-to-moderate kidney disease study. Clin Chem. 2007;53:1264–72.CrossRefPubMed Spanaus KS, Kronenberg F, Ritz E, Schlapbach R, Fliser D, Hersberger M, et al. B-type natriuretic peptide concentrations predict the progression of nondiabetic chronic kidney disease: the mild-to-moderate kidney disease study. Clin Chem. 2007;53:1264–72.CrossRefPubMed
15.
go back to reference Dieplinger B, Mueller T, Kollerits B, Struck J, Ritz E, von Eckardstein A, et al. Pro-A-type natriuretic peptide and pro-adrenomedullin predict progression of chronic kidney disease: the MMKD study. Kidney Int. 2009;75:408–14.CrossRefPubMed Dieplinger B, Mueller T, Kollerits B, Struck J, Ritz E, von Eckardstein A, et al. Pro-A-type natriuretic peptide and pro-adrenomedullin predict progression of chronic kidney disease: the MMKD study. Kidney Int. 2009;75:408–14.CrossRefPubMed
16.
go back to reference Landray MJ, Emberson JR, Blackwell L, Dasgupta T, Zakeri R, Morgan MD, et al. Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study. Am J Kidney Dis. 2010;56:1082–94.CrossRefPubMedPubMedCentral Landray MJ, Emberson JR, Blackwell L, Dasgupta T, Zakeri R, Morgan MD, et al. Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study. Am J Kidney Dis. 2010;56:1082–94.CrossRefPubMedPubMedCentral
17.
go back to reference Desai AS, Toto R, Jarolim P, Uno H, Eckardt KU, Kewalramani R, et al. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. Am J Kidney Dis. 2011;58:717–28.CrossRefPubMed Desai AS, Toto R, Jarolim P, Uno H, Eckardt KU, Kewalramani R, et al. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. Am J Kidney Dis. 2011;58:717–28.CrossRefPubMed
18.
go back to reference Fox CS, Gona P, Larson MG, Selhub J, Tofler G, Hwang SJ, et al. A multi-marker approach to predict incident CKD and microalbuminuria. J Am Soc Nephrol. 2010;21:2143–9.CrossRefPubMedPubMedCentral Fox CS, Gona P, Larson MG, Selhub J, Tofler G, Hwang SJ, et al. A multi-marker approach to predict incident CKD and microalbuminuria. J Am Soc Nephrol. 2010;21:2143–9.CrossRefPubMedPubMedCentral
19.
go back to reference Bansal N, Katz R, Dalrymple L, de Boer I, DeFilippi C, Kestenbaum B, et al. NT-proBNP and troponin T and risk of rapid kidney function decline and incident CKD in elderly adults. Clin J Am Soc Nephrol. 2015;10:205–14.CrossRefPubMedPubMedCentral Bansal N, Katz R, Dalrymple L, de Boer I, DeFilippi C, Kestenbaum B, et al. NT-proBNP and troponin T and risk of rapid kidney function decline and incident CKD in elderly adults. Clin J Am Soc Nephrol. 2015;10:205–14.CrossRefPubMedPubMedCentral
20.
go back to reference Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefPubMed Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefPubMed
21.
go back to reference Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90:195–203.CrossRefPubMed Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90:195–203.CrossRefPubMed
22.
go back to reference Kato J, Kitamura K, Matsui E, Tanaka M, Ishizaka Y, Kita T, et al. Plasma adrenomedullin and natriuretic peptides in patients with essential or malignant hypertension. Hypertens Res. 1999;22:61–5.CrossRefPubMed Kato J, Kitamura K, Matsui E, Tanaka M, Ishizaka Y, Kita T, et al. Plasma adrenomedullin and natriuretic peptides in patients with essential or malignant hypertension. Hypertens Res. 1999;22:61–5.CrossRefPubMed
23.
go back to reference Giannessi D, Andreassi MG, Del Ry S, Clerico A, Colombo MG, Dini N. Possibility of age regulation of the natriuretic peptide C-receptor in human platelets. J Endocrinol Invest. 2001;24:8–16.CrossRefPubMed Giannessi D, Andreassi MG, Del Ry S, Clerico A, Colombo MG, Dini N. Possibility of age regulation of the natriuretic peptide C-receptor in human platelets. J Endocrinol Invest. 2001;24:8–16.CrossRefPubMed
24.
go back to reference Sezai A, Hata M, Niino T, Yoshitake I, Unosawa S, Wakui S, et al. Results of low-dose human atrial natriuretic peptide infusion in nondialysis patients with chronic kidney disease undergoing coronary artery bypass grafting: the NU-HIT (Nihon University working group study of low-dose HANP Infusion Therapy during cardiac surgery) trial for CKD. J Am Coll Cardiol. 2011;58:897–903.CrossRefPubMed Sezai A, Hata M, Niino T, Yoshitake I, Unosawa S, Wakui S, et al. Results of low-dose human atrial natriuretic peptide infusion in nondialysis patients with chronic kidney disease undergoing coronary artery bypass grafting: the NU-HIT (Nihon University working group study of low-dose HANP Infusion Therapy during cardiac surgery) trial for CKD. J Am Coll Cardiol. 2011;58:897–903.CrossRefPubMed
25.
go back to reference Ng TM, Ackerbauer KA, Hyderi AF, Hshieh S, Elkayam U. Comparative effects of nesiritide and nitroglycerin on renal function, and incidence of renal injury by traditional and RIFLE criteria in acute heart failure. J Cardiovasc Pharmacol Ther. 2012;17:79–85.CrossRefPubMed Ng TM, Ackerbauer KA, Hyderi AF, Hshieh S, Elkayam U. Comparative effects of nesiritide and nitroglycerin on renal function, and incidence of renal injury by traditional and RIFLE criteria in acute heart failure. J Cardiovasc Pharmacol Ther. 2012;17:79–85.CrossRefPubMed
26.
go back to reference McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.CrossRefPubMed McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.CrossRefPubMed
27.
go back to reference Judge P, Haynes R, Landray MJ, Baigent C. Neprilysin inhibition in chronic kidney disease. Nephrol Dial Transplant. 2015;30:738–43.CrossRefPubMed Judge P, Haynes R, Landray MJ, Baigent C. Neprilysin inhibition in chronic kidney disease. Nephrol Dial Transplant. 2015;30:738–43.CrossRefPubMed
Metadata
Title
Plasma levels of natriuretic peptides and development of chronic kidney disease
Authors
Noriyuki Ogawa
Hiroshi Komura
Kenji Kuwasako
Kazuo Kitamura
Johji Kato
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2015
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-015-0163-9

Other articles of this Issue 1/2015

BMC Nephrology 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.